Evidence map›Paper›PMID 41560794›Full record

ArticleMaterials today. Bio2026

Genetically programmable protein-biomineral core-shell nanovectors for enhancing tumor microenvironment-activated chemotherapy.

Kaiyue Zhang, Xincheng Sun, Ting Ji, Xinchen Shen, Yao Li, Hang Zhao, Xinyi Yang, Hu Li, Wenwen Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kaiyue ZhangCentre for Regeneration and Cell Therapy, The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Xincheng SunCentre for Regeneration and Cell Therapy, The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Ting JiCentre for Regeneration and Cell Therapy, The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Xinchen ShenCentre for Regeneration and Cell Therapy, The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Yao LiInstitute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Hang ZhaoCentre for Regeneration and Cell Therapy, The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Xinyi YangCentre for Regeneration and Cell Therapy, The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Hu LiCentre for Regeneration and Cell Therapy, The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.
Wenwen HuangCentre for Regeneration and Cell Therapy, The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limited chemotherapy efficacy results in frequent treatment failure events in multiple malignant tumors. Because of limited aqueous solubility, short retention time in the tumor, lack of selectivity toward cancerous cells and non-specific toxicity, there is urgent demand for the discovery of innovative cancer drugs with improved efficacy and selectivity. While nanotechnology offers promising solutions for drug delivery, many nanocarriers still face challenges such as premature drug leakage during circulation, insufficient tumor-specific accumulation, and potential off-target toxicity. To address these limitations, we utilize genetically engineered silk-elastin-like proteins (SELPs) as potent tumor-responsive drug carriers. Tumor cells α

Indexed as

BiomineralizationNanomedicineRecombinant protein designTumor-responsiveTumor retention

Identifiers

PMID41560794
PMCPMC12813328

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.